Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors

Summary

Single center, single arm phase Ib trial to test the feasibility and safety of Tumor- Infiltrating Lymphocyte-Adoptive Cell Therapy (TIL-ACT) combined with low-dose irradiation in patients with advanced or metastatic solid tumors. The trial is based on lymphodepleting chemotherapy followed by low dose irradiation (LDI), and then ACT utilizing ex vivo expanded TILs in combination with high dose IL-2 (optional, depending on patient's tolerance). LDI will be administered once to metastatic lesions using tomotherapy.

Timeline

Start

2019-09-01

Primary completion

2021-03-05

Completion

2021-03-05

Outcome

Outcome not reported

Stopped: “Internal competitive study that is open”

Drugs

Indications